RT Journal Article
SR Electronic
T1 Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.08.24309596
DO 10.1101/2024.07.08.24309596
A1 Mungo, Chemtai
A1 Sorgi, Katherine
A1 Ogollah, Cirillus
A1 Misiko, Brenda
A1 Cheserem, Cynthia
A1 Githongo, George
A1 Omoto, Jackton
YR 2024
UL http://medrxiv.org/content/early/2024/08/12/2024.07.08.24309596.abstract
AB Cervical cancer remains a significant global health issue, especially in low- and middle-income countries (LMICs), where access to prevention and treatment is limited and women are at a higher risk of cervical cancer. Artesunate, a widely available drug used to treat malaria, has shown promise in treating human papillomavirus (HPV)-associated anogenital lesions including high-grade cervical precancer, in a recent Phase I studies in the United States. Data on the pharmacokinetics of artesunate following intravaginal use, and its implications on malaria resistance, are lacking.Objectives The primary objective of this study is to investigate the pharmacokinetics of Artesunate (AS) and its active metabolite, dihydroartemisinin (DHA) following intravaginal use at the dosing and frequency intended for cervical precancer treatment. A secondary objective is to assess safety among study participants.Methods We are conducting a single-arm, phase I trial with a sample size of 12 female volunteers. Participants will self-administer artesunate vaginal pessaries in the study clinic daily for 5 consecutive days. Participants will have their blood drawn prior to receiving the first dose of artesunate on day one of the study and then will receive 8 blood draws on study day five, prior to artesunate administration and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after pessary administration. Pharmacokinetic parameters of artesunate and DHA will be calculated by way of quantitative analysis of with determination of maximum concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration versus time curve (AUC), apparent clearance, and elimination half-life (t1/2).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT06263582Funding StatementThis research was supported by the Department of Obstetrics and Gynecology at University of North Carolina-Chapel Hill and the Womens Reproductive Health Research (WRHR) Career Development Program under award number 5-K12-HD103085-04. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study funders have no role in the research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical trial has full ethics review board approval from the University of North Carolina Chapel Hill and the African Medical Research Foundation. Written informed consent will be obtained from all study participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data to be produced in the present study will be available upon reasonable request to the authors LMICsLow- and middle-income countries:ASArtesunateWHOWorld Health OrganizationCIN2/3High-grade cervical intraepithelial neoplasiaHPVHuman papillomavirusDHADihydroartemisininPKPharmacokineticsIVIntravenousIMIntramuscularACTsArtemisinin-based combination therapies